CoChat

Galectin-3 in Microglia-Mediated Neuroinflammation: Implications for Central Nervous System Diseases

Open access
Tian, Yu-Ke, Ye, Da-Wei, Ge, Meng-Meng, Chen, Nan, Zhou, Ya-Qun, Yang, Hui · 2022 · Current Neuropharmacology

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

Abstract

Microglial activation is one of the common hallmarks shared by various central nervous system (CNS) diseases. Based on surrounding circumstances, activated microglia play either detrimental or neuroprotective effects. Galectin-3 (Gal-3), a group of β-galactoside-binding proteins, has been cumulatively revealed to be a crucial biomarker for microglial activation after injuries or diseases. In consideration of the important role of Gal-3 in the regulation of microglial activation, it might be a potential target for the treatment of CNS diseases. Recently, Gal-3 expression has been extensively investigated in numerous pathological processes as a mediator of neuroinflammation, as well as in cell proliferation. However, the underlying mechanisms of Gal-3 involved in microgliamediated neuroinflammation in various CNS diseases remain to be further investigated. Moreover, several clinical studies support that the levels of Gal-3 are increased in the serum or cerebrospinal fluid of patients with CNS diseases. Thus, we summarized the roles and underlying mechanisms of Gal-3 in activated microglia, thus providing a better insight into its complexity expression pattern, and contrasting functions in CNS diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1570159x20666220201094547

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. (1) The effects and underlying mechanisms of Gal-3 in the activation of immune cells in various diseases. AKT: protein kinase B; ERK: extracellular signal-regulated kinase; IL-1β: interleukin-1 beta; IL-4: interleukin-4; LPS: lipopolysaccharide; JNK1: c-Jun N-terminal kinase 1; MAPK: mitogen-activated protein kinase; PI3K: phosphatidylinositide 3-kinases; PKC: protein kinase C; ROS: reactive oxygen species. The figure was created using BioRender.com.
Fig. (1) The effects and underlying mechanisms of Gal-3 in the activation of immune cells in various diseases. AKT: protein kinase B; ERK: extracellular signal-regulated kinase; IL-1β: interleukin-1 beta; IL-4: interleukin-4; LPS: lipopolysaccharide; JNK1: c-Jun N-terminal kinase 1; MAPK: mitogen-activated protein kinase; PI3K: phosphatidylinositide 3-kinases; PKC: protein kinase C; ROS: reactive oxygen species. The figure was created using BioRender.com.CC BY-NC · PubMed Central
Fig. (2) Signaling mechanisms of Gal-3 involved in microglia-mediated proliferation, neuroinflammation, and phagocytosis in CNS diseases. (1) Secreted Gal-3 involved in microglia-mediated myelin phagocytosis via regulating K-Ras-GTP-dependent PI3K activity. Moreover, Gal-3 could also bind to MerTK or interact with TREM2/DAP12 signaling, thus regulating microglia-mediated phagocytosis. (2-3) Gal-3 could interact with TREM2/DAP12 signaling, participating in various biological processes, including DAM activation or microglial proliferation. (4) Gal-3 could also bind to IGFR and is involved in the IGF-1-mediated proliferation of microglia. (5) Gal-3 released by activated microglia could directly interact with TLRs or TREM2, thus exacerbating the release of inflammatory factors. DAM: microglia phenotype associated with neurodegenerative diseases; DAP12: DNAX-activating protein of 12 kDa; Gal-3: galectin-3; IGF-1: insulin-like growth factor 1; IGF-R1: insulin-like growth factor receptor 1; JNK: c-Jun N-terminal kinase; MerTK: Mer tyrosine kinase; NF-κB: nuclear factor-κB; PI3K: phosphatidylinositide 3-kinases; STAT3: signal transducer and activator of transcription 3; TLRs: Toll-like receptors; TREM2: triggering receptor expressed on myeloid cell 2. The figure was created using BioRender.com.
Fig. (2) Signaling mechanisms of Gal-3 involved in microglia-mediated proliferation, neuroinflammation, and phagocytosis in CNS diseases. (1) Secreted Gal-3 involved in microglia-mediated myelin phagocytosis via regulating K-Ras-GTP-dependent PI3K activity. Moreover, Gal-3 could also bind to MerTK or interact with TREM2/DAP12 signaling, thus regulating microglia-mediated phagocytosis. (2-3) Gal-3 could interact with TREM2/DAP12 signaling, participating in various biological processes, including DAM activation or microglial proliferation. (4) Gal-3 could also bind to IGFR and is involved in the IGF-1-mediated proliferation of microglia. (5) Gal-3 released by activated microglia could directly interact with TLRs or TREM2, thus exacerbating the release of inflammatory factors. DAM: microglia phenotype associated with neurodegenerative diseases; DAP12: DNAX-activating protein of 12 kDa; Gal-3: galectin-3; IGF-1: insulin-like growth factor 1; IGF-R1: insulin-like growth factor receptor 1; JNK: c-Jun N-terminal kinase; MerTK: Mer tyrosine kinase; NF-κB: nuclear factor-κB; PI3K: phosphatidylinositide 3-kinases; STAT3: signal transducer and activator of transcription 3; TLRs: Toll-like receptors; TREM2: triggering receptor expressed on myeloid cell 2. The figure was created using BioRender.com.CC BY-NC · PubMed Central
Fig. (3) The underlying mechanisms of Gal-3 that participate in the development of different types of pathological pain. (1) The possible mechanisms of Gal-3 that participate in the development of HZ-induced neuropathic pain. (2) Gal-3 inhibition could remarkably suppress SNL-induced neuroinflammation and neuropathic pain, at least in part via regulating autophagy activation. (3) Gal-3 plays a crucial role in aggravating the neuroinflammation of SCI rats via regulating the activation of the ROS/TXNIP/NLRP3 signaling pathway. Inhibition of Gal-3 improved the functional recovery of SCI rats via regulating the polarization of microglia towards the M2 phenotype. (4) Overexpression of miR-185 suppresses IDD-induced apoptosis and cell autophagy through suppression of the Wnt/β-catenin signaling pathway via regulating Gal-3. ERK: extracellular signal-regulated kinase; Gal-3: galectin-3; HZ: herpes zoster; IDD: intervertebral disc degeneration; LC-3: microtubule-associated protein 1 light chain 3; NLRP3: nod-like receptor protein 3; ROS: reactive oxygen species; SCI: spinal cord injury; SNL: spinal nerve ligation; TLR-4: Toll-like receptor-4; Trx: thioredoxin; TXNIP: thioredoxin-interacting protein. The figure was created using BioRender.com.
Fig. (3) The underlying mechanisms of Gal-3 that participate in the development of different types of pathological pain. (1) The possible mechanisms of Gal-3 that participate in the development of HZ-induced neuropathic pain. (2) Gal-3 inhibition could remarkably suppress SNL-induced neuroinflammation and neuropathic pain, at least in part via regulating autophagy activation. (3) Gal-3 plays a crucial role in aggravating the neuroinflammation of SCI rats via regulating the activation of the ROS/TXNIP/NLRP3 signaling pathway. Inhibition of Gal-3 improved the functional recovery of SCI rats via regulating the polarization of microglia towards the M2 phenotype. (4) Overexpression of miR-185 suppresses IDD-induced apoptosis and cell autophagy through suppression of the Wnt/β-catenin signaling pathway via regulating Gal-3. ERK: extracellular signal-regulated kinase; Gal-3: galectin-3; HZ: herpes zoster; IDD: intervertebral disc degeneration; LC-3: microtubule-associated protein 1 light chain 3; NLRP3: nod-like receptor protein 3; ROS: reactive oxygen species; SCI: spinal cord injury; SNL: spinal nerve ligation; TLR-4: Toll-like receptor-4; Trx: thioredoxin; TXNIP: thioredoxin-interacting protein. The figure was created using BioRender.com.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 115 references

Cited by

See all 36

Metadata

Authors
Tian, Y.-K., Ye, D.-W., Ge, M.-M., Chen, N., Zhou, Y.-Q., & Yang, H.
Affiliations
  • Tongji Hospital (CN)
  • Shanxi Medical University (CN)
Corresponding author
  • Tian, Yu-Ke
  • Ye, Da-Wei
Venue
Current Neuropharmacology
Published
2022-11
Volume
20
Issue
11
Pages
2066-2080
ISSN
1570-159X (ISSN-L)
OpenAlex
W4210539427
Cited by
31
References
113
Citations by year
2026: 3 · 2025: 11 · 2024: 12 · 2023: 4 · 2022: 1
FWCI
2.46
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Current Neuropharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (81873732, 81400917)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
Keywords
galectin-3, microglial activation, neuroinflammation, central nervous system disorders, neuroprotection, biomarkers, cerebrospinal fluid, serum biomarkers, therapeutic target, cell proliferation
MeSH terms
Neuroinflammatory Diseases, Blood Proteins, Central Nervous System Diseases, Humans, Microglia, Galectins, Galectin 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Galectin-3 in Microglia-Mediated Neuroinflammation: Implications for Central Nervous System Diseases. https://app.cochat.ai/papers/10.2174/1570159x20666220201094547
The paper
Tian, Y.-K., Ye, D.-W., Ge, M.-M., Chen, N., Zhou, Y.-Q., & Yang, H. (2022). Galectin-3 in Microglia-Mediated Neuroinflammation: Implications for Central Nervous System Diseases. Current Neuropharmacology. https://doi.org/10.2174/1570159x20666220201094547

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.